20 completed, 11 recruiting, 6 withdrawn, 5 active not recruiting. 48 Phase 2, 17 Phase 1.
Follow Leukapheresis: new trials by email Literature Review of Leukapheresis trials Research Report on Leukapheresis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Recruiting | Uma Borate | 70 | 2026-10-01 | 2026-08-27 |
| GLORY: Glofit-GemOx With Liso-Cel For Lymphoma Obinutuzumab, Glofitamab, Gemcitabine & oxaliplatin - Lymphoma, B-cell Lymphomas | Phase 2 | Recruiting | Massachusetts General Hospital | 56 | 2026-09-15 | 2026-10-22 |
| Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma Leukapheresis, Lymphodepleting Chemotherapy - Large B-cell Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2026-03-17 | 2026-06-30 |
| Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells Axicabtagene Ciloleucel, Biospecimen Collection, Chemotherapy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Phase 2 | Recruiting | City of Hope Medical Center | 56 | 2026-02-11 | 2026-03-05 |
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Suspended | Fred Hutchinson Cancer Center | 33 | 2025-12-27 | 2026-09-11 |
| Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T Odronextamab, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of Washington | 27 | 2025-09-04 | 2026-08-28 |
| Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Mayo Clinic | 41 | 2025-04-02 | 2026-10-20 |
| Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma Leukapheresis, Bridging Therapy, Lymphodepletion - B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent | Phase 2 | Terminated | Universität Münster | 1 | 2025-03-13 | 2025-09-04 |
| Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer Alpha-type-1 Polarized Dendritic Cells, Biopsy, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2025-02-01 | 2025-01-29 | |
| Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Anti-STEAP1 CAR T-cells, Biopsy Procedure, Biospecimen Collection - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 48 | 2024-11-26 | 2026-08-11 |
| Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial Biopsy, Biospecimen Collection, Computed Tomography - Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | Mayo Clinic | 78 | 2024-11-12 | 2026-10-02 |
| Pembro Plus CAR T-cell Therapy in R/R in PMBCL Pembrolizumab, Lymphodepletion Chemotherapy, Chimeric Antigen Receptor (CAR) Therapy Infusion - Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma | Phase 2 | Recruiting | Jennifer Crombie, MD | 35 | 2023-11-15 | 2026-03-05 |
| Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia | Phase 2 | Recruiting | Aseel Alsouqi | 24 | 2023-07-28 | 2026-03-03 |
| Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML Cytokine induced memory-like NK cells, Fludarabine, Ara-C - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 2 | Withdrawn | Washington University School of Medicine | 2023-06-30 | 2023-04-04 | |
| A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors Single Injection of IVS-3001- Anti - HLA-G CAR-T cells, Fludarabine phosphate, Cyclophosphamide - Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 31 | 2023-06-21 | 2026-06-25 |
| Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma Lenalidomide, bb2121, Cyclophosphamide - Multiple Myeloma | Phase 2 | Completed | Medical College of Wisconsin | 40 | 2022-01-05 | 2026-05-19 |
| Liver Transplantation With Tregs at UCSF arTreg, leukapheresis, cyclophosphamide - Liver Transplant | Phase 1 / Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 42 | 2021-04-22 | 2024-04-23 |
| Stem Cell Transplantation in Crohn's Disease Mesna, Cyclophosphamide, Filgrastim - Crohn Disease | Phase 1 / Phase 2 | Recruiting | Cedars-Sinai Medical Center | 15 | 2019-11-15 | 2026-02-20 |
| Liver Transplantation With Tregs at MGH arTreg-CSB, leukapheresis, cyclophosphamide - Liver Transplant | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 9 | 2019-03-29 | 2026-09-16 |
| Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma Bendamustine, Rituximab, Acalabrutinib - Mantle Cell Lymphoma | Phase 2 | Completed | Washington University School of Medicine | 13 | 2018-11-29 | 2026-04-21 |
Showing 20 of 48. Sign in to see all of them.
Multiple Myeloma (8) · Lymphoma, Large B-Cell, Diffuse (7) · Leukemia, Myeloid, Acute (6) · Lymphoma, Non-Hodgkin (6) · Hodgkin Disease (4) · Breast Neoplasms (3) · Hematologic Neoplasms (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Mantle-Cell (3) · Breast Neoplasms, Male (2) · Crohn Disease (2) · HIV Infections (2) · Hematologic Diseases (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Lymphoma (2)
Washington University School of Medicine (8) · Fred Hutchinson Cancer Center (5) · M.D. Anderson Cancer Center (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · University of Washington (4) · City of Hope Medical Center (2) · Mayo Clinic (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Roswell Park Cancer Institute (2) · Aseel Alsouqi (1) · Barbara Ann Karmanos Cancer Institute (1) · Canadian Immunodeficiency Research Collaborative (1) · Cedars-Sinai Medical Center (1) · Dana-Farber Cancer Institute (1) · Imperial College London (1)
United States (43) · Canada (1) · Germany (1) · United Kingdom (1)
Amanda Cashen, M.D. (3) · Mary Disis (2) · Sergio Giralt, MD (2) · Ajay Gopal (1) · Alexandre V. Hirayama, MD (1) · Alfred Garfall, MD (1) · Amanda F. Cashen, M.D. (1) · Amir A Jazaeri (1) · Ann Traynor, MD (1) · Ann Woolfrey (1) · Aung Naing, MD (1) · Betty Diamond, MD (1) · Bevra Hahn, MD (1) · Brad S Kahl, M.D. (1) · Chitra Hosing, MD (1)
PMID 27190628, PMID 28292947, PMID 34515338, PMID 34797911, PMID 34871371, PMID 35196021
P30CA015704 (2), P50CA171963 (2), F32CA200253 (1), P01CA018029 (1), P30CA016056 (1), P30CA022453 (1), P30CA033572 (1), P50CA097186 (1), R01CA129517 (1), R01CA164333 (1), U01HL069294 (1), U10HL069294 (1), U19AI096111 (1), U24CA076518 (1), UM1AI109565 (1)